Intra-Cellular Therapies (ITCI) shares rallied 9.6% in the last trading session to close at $75.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.4$0.20 per share in its upcoming report, which represents a year-over-year change of +55.6%. Revenues are expected to be $157.59 million, up 42.2% from the year ...